ProMark: a first-of-its-kind protein based prognostic test for Prostate Cancer
Predict cancer aggressiveness* in patients with biopsy Gleason Scores of 3+3 and 3+4.
- Provides a personalized prediction that the cancer can be managed without aggressive treatment, or an indication that aggressive therapy may be appropriate
- Powerful, independent risk predictor for Prostate Cancer
- Objective and fully reproducible
- Predictive of disease aggressiveness throughout the prostate, reducing sampling error
- Outperforms and requires substantially less tissue than conventional gene-expression-based Prostate Cancer prognostic tests
- Cutting edge, automated image recognition technology provides objective identification of tumor cells and quantitative measurement of predictive protein biomarker expression levels
- Generates an individual risk score delivered within an intuitive report allowing for productive discussion with your patient
- Specific: Developed exclusively for use on prostate biopsy tissue
- Unique, 8-protein signature
- Strong clinical validation
- Included in the NCCN Clinical Care Guidelines
User Sign in